207 related articles for article (PubMed ID: 19219381)
1. Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states.
Nuche-Berenguer B; Moreno P; Esbrit P; Dapía S; Caeiro JR; Cancelas J; Haro-Mora JJ; Villanueva-Peñacarrillo ML
Calcif Tissue Int; 2009 Jun; 84(6):453-61. PubMed ID: 19219381
[TBL] [Abstract][Full Text] [Related]
2. Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states.
Nuche-Berenguer B; Moreno P; Portal-Nuñez S; Dapía S; Esbrit P; Villanueva-Peñacarrillo ML
Regul Pept; 2010 Jan; 159(1-3):61-6. PubMed ID: 19586609
[TBL] [Abstract][Full Text] [Related]
3. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?
Avbersek-Luznik I; Balon BP; Rus I; Marc J
Nephrol Dial Transplant; 2005 Mar; 20(3):566-70. PubMed ID: 15665031
[TBL] [Abstract][Full Text] [Related]
4. Normalizing action of exendin-4 and GLP-1 in the glucose metabolism of extrapancreatic tissues in insulin-resistant and type 2 diabetic states.
Moreno P; Nuche-Berenguer B; Gutiérrez-Rojas I; Acitores A; Sancho V; Valverde I; González N; Villanueva-Peñacarrillo ML
J Mol Endocrinol; 2012 Feb; 48(1):37-47. PubMed ID: 22065862
[TBL] [Abstract][Full Text] [Related]
5. Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes.
Kim JY; Lee SK; Jo KJ; Song DY; Lim DM; Park KY; Bonewald LF; Kim BJ
Life Sci; 2013 Mar; 92(10):533-40. PubMed ID: 23357248
[TBL] [Abstract][Full Text] [Related]
6. Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease.
Doumouchtsis K; Perrea D; Doumouchtsis S; Tziamalis M; Poulakou M; Vlachos I; Kostakis A
Ther Apher Dial; 2009 Feb; 13(1):49-55. PubMed ID: 19379170
[TBL] [Abstract][Full Text] [Related]
7. Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice.
Iida-Klein A; Zhou H; Lu SS; Levine LR; Ducayen-Knowles M; Dempster DW; Nieves J; Lindsay R
J Bone Miner Res; 2002 May; 17(5):808-16. PubMed ID: 12009011
[TBL] [Abstract][Full Text] [Related]
8. Amylin exerts osteogenic actions with different efficacy depending on the diabetic status.
Gutiérrez-Rojas I; Lozano D; Nuche-Berenguer B; Moreno P; Acitores A; Ramos-Álvarez I; Rovira A; Novials A; Martín-Crespo E; Villanueva-Peñacarrillo ML; Esbrit P
Mol Cell Endocrinol; 2013 Jan; 365(2):309-15. PubMed ID: 23178165
[TBL] [Abstract][Full Text] [Related]
9. Osteoclastic function is accelerated in male patients with type 2 diabetes mellitus: the preventive role of osteoclastogenesis inhibitory factor/osteoprotegerin (OCIF/OPG) on the decrease of bone mineral density.
Suzuki K; Kurose T; Takizawa M; Maruyama M; Ushikawa K; Kikuyama M; Sugimoto C; Seino Y; Nagamatsu S; Ishida H
Diabetes Res Clin Pract; 2005 May; 68(2):117-25. PubMed ID: 15860239
[TBL] [Abstract][Full Text] [Related]
10. Anabolic Effect of Insulin Therapy on the Bone: Osteoprotegerin and Osteocalcin Up-Regulation in Streptozotocin-Induced Diabetic Rats.
Bortolin RH; Freire Neto FP; Arcaro CA; Bezerra JF; da Silva FS; Ururahy MA; Souza KS; Lima VM; Luchessi AD; Lima FP; Lia Fook MV; da Silva BJ; Almeida MD; Abreu BJ; de Rezende LA; de Rezende AA
Basic Clin Pharmacol Toxicol; 2017 Mar; 120(3):227-234. PubMed ID: 27651300
[TBL] [Abstract][Full Text] [Related]
11. Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin.
Li X; Ominsky MS; Stolina M; Warmington KS; Geng Z; Niu QT; Asuncion FJ; Tan HL; Grisanti M; Dwyer D; Adamu S; Ke HZ; Simonet WS; Kostenuik PJ
Bone; 2009 Oct; 45(4):669-76. PubMed ID: 19539794
[TBL] [Abstract][Full Text] [Related]
12. Glucagon like peptide 2 has a positive impact on osteoporosis in ovariectomized rats.
Xu B; He Y; Lu Y; Ren W; Shen J; Wu K; Xu K; Wu J; Hu Y
Life Sci; 2019 Jun; 226():47-56. PubMed ID: 30959027
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of genistein and zoledronic acid on the bone loss in OPG-deficient mice.
Liu J; Xu K; Wen G; Guo H; Li S; Wu X; Dai R; Sheng Z; Liao E
Bone; 2008 May; 42(5):950-9. PubMed ID: 18337202
[TBL] [Abstract][Full Text] [Related]
14. Effects of the linagliptin, dipeptidyl peptidase-4 inhibitor, on bone fragility induced by type 2 diabetes mellitus in obese mice.
Kanda J; Furukawa M; Izumo N; Shimakura T; Yamamoto N; Takahashi HE; Wakabayashi H
Drug Discov Ther; 2020 Nov; 14(5):218-225. PubMed ID: 33116039
[TBL] [Abstract][Full Text] [Related]
15. Fish liver oil and propolis as protective natural products against the effect of the anti-epileptic drug valproate on immunological markers of bone formation in rats.
Elwakkad AS; El Elshamy KA; Sibaii H
Epilepsy Res; 2008 Jul; 80(1):47-56. PubMed ID: 18455911
[TBL] [Abstract][Full Text] [Related]
16. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
Vilsbøll T; Knop FK; Krarup T; Johansen A; Madsbad S; Larsen S; Hansen T; Pedersen O; Holst JJ
J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471
[TBL] [Abstract][Full Text] [Related]
17. Tartrate-resistant acid phosphatase 5b and its correlations with other markers of bone metabolism in kidney transplant recipients and dialyzed patients.
Małyszko J; Małyszko JS; Pawlak K; Wołczyński S; Myśliwiec M
Adv Med Sci; 2006; 51():69-72. PubMed ID: 17357281
[TBL] [Abstract][Full Text] [Related]
18. Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose tolerance.
Jørgensen NB; Jacobsen SH; Dirksen C; Bojsen-Møller KN; Naver L; Hvolris L; Clausen TR; Wulff BS; Worm D; Lindqvist Hansen D; Madsbad S; Holst JJ
Am J Physiol Endocrinol Metab; 2012 Jul; 303(1):E122-31. PubMed ID: 22535748
[TBL] [Abstract][Full Text] [Related]
19. Vitamin K2 inhibits glucocorticoid-induced bone loss partly by preventing the reduction of osteoprotegerin (OPG).
Sasaki N; Kusano E; Takahashi H; Ando Y; Yano K; Tsuda E; Asano Y
J Bone Miner Metab; 2005; 23(1):41-7. PubMed ID: 15616893
[TBL] [Abstract][Full Text] [Related]
20. Circulating levels of tartrate-resistant acid phosphatase in rat models of non-insulin-dependent diabetes mellitus.
Suzuki K; Ishida H; Takeshita N; Taguchi Y; Sugimoto C; Nosaka K; Seino Y
J Diabetes Complications; 1998; 12(3):176-80. PubMed ID: 9618074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
